cervical cancer, making it the third most common cancer in New Zealand for women aged 25-44. At least 50 women will die from this cancer annually. In 2006 Gardasil, a vaccination produced by Merck, was approved by the FDA (Food and Drug Administration), as a vaccine for females aged 9-26, to combat HPV strains known to lead to cancer. In 2008 the Gardasil immunization was added to New Zealand’s immunization schedule and in 2009, this vaccination began to be administered in schools. Not only is New Zealand
cancer cases (Thomas, 2008). The Food and Drug Administration licensed the vaccine, Gardasil, produced by the pharmaceutical company, Merck, in June 2006 as a safe and effective means for preventing cervical cancer caused by HPV (Thomas, 2008). The vaccine can be administered in young girls starting at the age of 9 years old and has been recommended for all girls and women between the ages of 13 and 26 years old with the vaccine being most effective prior to beginning sexual activity (Thomas, 2008).